Camp4 Therapeutics Corp
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Camp4 Therapeutics is a biopharmaceutical company developing RNA-guided therapies that target regulatory RNA to modulate gene expression, aiming to treat genetically defined diseases by restoring protein levels rather than fully replacing genes.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Tardiff DanielChief Scientific Officer | Sell | $8K | 1,738at $4.76 | Aug 19, 2026 |
| Young Richard ADirector | Buy | $27K | 16,378at $1.65 | Aug 3, 2026 |
| Maricich YuriChief Medical Officer | Buy | $11K | 6,551at $1.65 | Aug 3, 2026 |
| Gold KellyChief Financial Officer | Buy | $11K | 6,551at $1.65 | Aug 3, 2026 |
| Mandel-Brehm JoshChief Executive Officer | Buy | $11K | 6,551at $1.65 | Aug 3, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable CAMP activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.